Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

BACKGROUND: L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we evaluated effects of L-BLP25 combined with low-dose cyclophosphamide (CPA) pretreat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurz, Gregory T, Gutierrez, Audrey M, Greenberg, Brittany E, Vang, Daniel P, Griffey, Stephen M, Kao, Chiao-Jung, Wolf, Michael, DeGregorio, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605365/
https://www.ncbi.nlm.nih.gov/pubmed/23496860
http://dx.doi.org/10.1186/1479-5876-11-64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605365/
https://www.ncbi.nlm.nih.gov/pubmed/23496860
http://dx.doi.org/10.1186/1479-5876-11-64

Ejemplares similares